These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 11190365)

  • 21. CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients.
    Peñas-Lledó EM; Trejo HD; Dorado P; Ortega A; Jung H; Alonso E; Naranjo ME; López-López M; Llerena A
    Mol Psychiatry; 2013 Jan; 18(1):8-9. PubMed ID: 22733128
    [No Abstract]   [Full Text] [Related]  

  • 22. Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode.
    Pintor L; Baillès E; Valldeoriola F; Tolosa E; Martí MJ; de Pablo J
    Gen Hosp Psychiatry; 2006; 28(1):59-64. PubMed ID: 16377367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe urinary retention requiring urinary catheterization associated with combined treatment of depression with duloxetine and quetiapine.
    Wang SM; Lee KU; Jeon YW; Park EJ; Han SI
    Psychiatry Clin Neurosci; 2013 Apr; 67(3):191. PubMed ID: 23581874
    [No Abstract]   [Full Text] [Related]  

  • 24. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
    Greist J; McNamara RK; Mallinckrodt CH; Rayamajhi JN; Raskin J
    Clin Ther; 2004 Sep; 26(9):1446-55. PubMed ID: 15531007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reboxetine treatment and pseudopheochromocytoma.
    Zornitzki T; Knobler H; Schattner A
    QJM; 2007 Jan; 100(1):61-2. PubMed ID: 17175558
    [No Abstract]   [Full Text] [Related]  

  • 26. Fluoxetine-induced mania in an Asian patient.
    Pae CU; Lee CU; Lee SJ; Lee C; Paik IH
    Psychiatry Clin Neurosci; 2004 Aug; 58(4):448-9. PubMed ID: 15298662
    [No Abstract]   [Full Text] [Related]  

  • 27. Antidepressant-suicide link in children questioned.
    Devi S
    Lancet; 2012 Mar; 379(9818):791. PubMed ID: 22393572
    [No Abstract]   [Full Text] [Related]  

  • 28. Dangerous interaction with nefazodone added to fluoxetine, desipramine, venlafaxine, valproate and clonazepam combination therapy.
    Benazzi F
    J Psychopharmacol; 1997; 11(2):190-1. PubMed ID: 9208383
    [No Abstract]   [Full Text] [Related]  

  • 29. Melancholic symptoms during concurrent olanzapine and fluoxetine.
    Nelson LA; Swartz CM
    Ann Clin Psychiatry; 2000 Sep; 12(3):167-70. PubMed ID: 10984007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Escitalopram/reboxetine combination in depressed patients with substance use disorder.
    Camarasa X; Lopez-Martinez E; Duboc A; Khazaal Y; Zullino DF
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):165-8. PubMed ID: 15610962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients.
    Gałecki P; Szemraj J; Bieńkiewicz M; Zboralski K; Gałecka E
    Hum Psychopharmacol; 2009 Jun; 24(4):277-86. PubMed ID: 19319921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
    Roberts RL; Mulder RT; Joyce PR; Luty SE; Kennedy MA
    Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reboxetine and hyponatremia.
    Ranieri P; Franzoni S; Trabucchi M
    N Engl J Med; 2000 Jan; 342(3):215-6. PubMed ID: 10651558
    [No Abstract]   [Full Text] [Related]  

  • 34. Pulmonary embolism from persistent dilatation of the bladder secondary to anticholinergic side effects.
    Ito M; Hatta K; Miyakawa K; Arai H
    Gen Hosp Psychiatry; 2009; 31(2):187-9. PubMed ID: 19269543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Augmentation strategies in the treatment of major depressive disorder. Clinical considerations with atypical antipsychotic augmentation.
    Gitlin MJ
    CNS Spectr; 2007 Dec; 12(12 Suppl 22):13-5. PubMed ID: 18389929
    [No Abstract]   [Full Text] [Related]  

  • 36. Urinary retention caused after fluoxetine-risperidone combination.
    Bozikas V; Petrikis P; Karavatos A
    J Psychopharmacol; 2001 Jun; 15(2):142-3. PubMed ID: 11448089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sexual dysfunction caused by reboxetine.
    Haberfellner EM
    Pharmacopsychiatry; 2002 Mar; 35(2):77-8. PubMed ID: 11951150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial.
    Amini H; Aghayan S; Jalili SA; Akhondzadeh S; Yahyazadeh O; Pakravan-Nejad M
    J Clin Pharm Ther; 2005 Apr; 30(2):133-8. PubMed ID: 15811165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ecchymoses as an adverse effect of fluoxetine treatment.
    Fountoulakis KN; Samolis S; Iacovides A; St Kaprinis G
    Psychiatry Res; 2007 Jul; 152(1):91-2. PubMed ID: 17445912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Galantamine as an adjunctive treatment in major depression.
    Elgamal S; MacQueen G
    J Clin Psychopharmacol; 2008 Jun; 28(3):357-9. PubMed ID: 18480702
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.